ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)

摘要

BACKGROUNDBortezomib is a slowly reversible proteasome inhibitor. Anti-tumor activity of bortezomib has shown efficacy towards GBM cell lines. Study has also demonstrated that the bortezomib is a potential caspase dependent apoptosis inducer in GBM cells. Our phase II study is to assess the safety and efficacy of bortezomib in combination with temozolomide and radiation therapy (RT) followed by bortezomib and temozolomide for up to 24 cycles of adjuvant therapy for the upfront treatment of patients with newly-diagnosed GBM.